ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jan 2, 2018
2018 Healthcare and Biotech Outlook
Image Source: Global Panorama. 2017 will undoubtedly go down as one of the most fabulous years for the stock market, and while we continue to warn of the dangers associated with the market continuing to trade at lofty valuations, we are intrigued by the outlook for big cap pharma and biotech in the near term. Changes in the US tax laws will likely have a profound impact on the industry.
Dec 26, 2017
Tweaking the Newsletter Portfolios for a Rising Interest-Rate Environment
Image Source: CreditCafe.com. Many market observers are anticipating the Fed to accelerate the pace of interest-rate hikes in 2018. We’re making a number of changes to the Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio as we consider what a higher interest-rate environment might look like. We’re also cognizant of the impact that higher interest rates may have on the High Yield Dividend Newsletter and its simulated portfolio, the first edition to be released January 1, 2018.
Dec 22, 2017
Boeing’s Big Dividend Hike; Potential Deal with Embraer
Image Source: Boeing. We love Boeing. The company has been one of our favorites for years, but its performance during 2017 has simply been amazing. The dividend growth giant upped its payout in a big way recently, too, even as it is reportedly pursuing merger discussions with Embraer.
Dec 10, 2017
Global Blood Therapeutics Follow Up
Image Source: Biotechnology Innovation Organization. In this piece, let’s discuss the recent positive events that have unfolded for Global Blood Therapeutics.
Dec 9, 2017
BioMarin Pharmaceuticals: A Rare Drug Powerhouse
Image shown: BioMarin's stock price has had a choppy ride these past couple years. BioMarin continues its impressive string of hits in the rare drug market. We continue to be impressed with the depth of the scientific advances brought forth by the company. An in-depth discussion of BioMarin's pipeline is warranted, in our view, particularly in light of the potential for an expected, upcoming FDA approval.
Dec 8, 2017
Dividend Increases/Decreases for the Week Ending December 8
Let's take a look at companies raising/lowering their dividends this week.
Dec 1, 2017
Shopping for Income Within Retail in a Digital World
Image Source: Mike Mozart. The 2017 holiday shopping season has shown that e-commerce has never been stronger and it will only continue to grow. But there is still potential for income generation among more traditional retailers. Investors must be tremendously discerning in the retail area, however, as margin, and ultimately free cash flow, pressures remain prevalent. We like Walmart, Target, Costco as income ideas in the broader retail space, but TJX Companies and Best Buy may be worth a look, too. We're avoiding the department stores and teen retail like the plague, regardless of their Dividend Cushion ratios.
Dec 1, 2017
Dividend Increases/Decreases for the Week Ending December 1
Let's take a look at companies raising/lowering their dividends this week.
Nov 19, 2017
Dividend Increases/Decreases for the Week Ending November 17
Let's take a look at companies raising/lowering their dividends this week.
Nov 10, 2017
Qualcomm Surges to Fair Value on Broadcom Offer
Shares of Qualcomm have faced meaningful pressure for the majority of 2017 as it deals with a legal battle with Apple, but the stock has rallied after Broadcom offered the firm a deal worth $70 per share in cash and stock.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.